Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Branch Chain Amino Acids vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of Hepatic Encephalopathy: Double-blind Placebo-controlled Multicentric Randomized Controlled Trial

NCT06538077 is registered in ClinicalTrials.gov with Post Graduate Institute of Medical Education and Research, Chandigarh as lead sponsor.

NCT NCT06538077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06538077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Branch Chain Amino Acids vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of Hepatic Encephalopathy: Double-blind Placebo-controlled Multicentric Randomized Controlled Trial
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase
Phase 4
Overall status
Recruiting
Start date
February 1, 2025
Completion date
August 31, 2027
Enrollment
336 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

decompensated cirrhosis, hepatic encephalopathy, minimal hepatic encephalopathy